The Impact of Genetic Variation in CYP2D6 on the Pharmacokinetics and Pharmacodynamics of Methamphetamine
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Methamphetamine abuse and addiction are widespread and is causing increasing pressures on
social, public health and criminal justice systems worldwide. Some of the risk for developing
addiction may be genetic. Identifying specific genotypes and understanding their interactions
with the environment may help predict who is at risk for developing a disease. In this study
the investigators are evaluating the contribution of differences in one genotype - called
CYP2D6 to the removal of methamphetamine from the body. Methamphetamine is removed from the
body by special enzymes in the liver. One of these enzymes is called Cytochrome P450 2D6. The
activity of 2D6 is genetically determined. Some people have no active 2D6 whereas in others
2D6 is very active. One group of scientists found that people with low 2D6 activity were less
likely to become methamphetamine addicts. In this study the investigators will determine the
activity of your 2D6 by looking at the CYP2D6 genotype. If low levels of 2D6 decrease the
risk of methamphetamine addiction it may be because there is less of the chemicals (called
metabolites) made by 2D6. The first step in the metabolism (the process of removal of drugs
from the body) of methamphetamine by 2D6 is conversion of methamphetamine to amphetamine and
para-hydroxymethamphetamine. 2D6 then converts these to inactive chemicals. In addition to
determining your genotype, the investigators are interested in the relationship of genotype
with the methamphetamine metabolism. Thus, as part of this study, you will be given a modest
oral dose of 5 milligrams of methamphetamine. After receiving the methamphetamine you will
need to collect your urine for 24 hours.
The purpose of this study is to investigate the impact of genetic variation in CYP2D6 on the
disposition of methamphetamine in the human body as well as its pharmacologic effects to
humans.
Phase:
Phase 4
Details
Lead Sponsor:
California Pacific Medical Center Research Institute
Collaborators:
Children's Mercy Hospital Kansas City The Children's Mercy Hospital